MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

Last update: 8 hours ago

109.75

-0.67 (-0.61%)

  • 1D -0.61%
  • 5D 0.32%
  • 1M -7.49%
  • 6M -12.36%
  • YTD -3.08%
  • 1Y 7.61%
  • 5Y 35.83%
Previous Close 110.42
Open 110.14
Volume 8,506,663
Avg. Volume (3M) 9,573,550
Market Cap 278,195,404,800
Price / Earnings (TTM) 20.32
Price / Earnings (Forward) 11.09
Price / Sales 4.46
Price / Book 6.36
52 Weeks Range
99.14 (-9%) — 134.63 (22%)
Earnings Date 31 Oct 2024
TTM Dividend Yield 2.81%
Profit Margin 21.99%
Operating Margin (TTM) 43.55%
Diluted EPS (TTM) 5.40
Quarterly Revenue Growth (YOY) 7.20%
Total Debt/Equity (MRQ) 86.57%
Current Ratio (MRQ) 1.47
Operating Cash Flow (TTM) 16.69 B
Levered Free Cash Flow (TTM) 11.79 B
Return on Assets (TTM) 11.38%
Return on Equity (TTM) 33.38%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bullish
Drug Manufacturers - General (Global) Bullish Bullish
Stock Merck & Company, Inc. Bearish Bullish

Stockmoo Score

1.5
Analyst Consensus 4.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 2.5
Technical Oscillators -2.5
Average 1.50

Similar Stocks

Stock Market Cap DY P/E P/B
MRK 278 B 2.81% 20.32 6.36
JNJ 396 B 2.96% 27.19 5.53
ABBV 285 B 2.84% 48.13 49.63
PFE 166 B 5.71% - 1.92
BMY 106 B 4.52% - 6.36
GSK 79 B 2.94% 13.89 4.26

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.06%
% Held by Institutions 79.06%

Ownership

Name Date Shares Held
Wellington Management Group Llp 30 Jun 2024 72,481,979
Price T Rowe Associates Inc /Md/ 30 Jun 2024 24,725,061
52 Weeks Range
99.14 (-9%) — 134.63 (22%)
Price Target Range
115.00 (4%) — 155.00 (41%)
High 155.00 (Cantor Fitzgerald, 41.23%) Buy
Median 136.00 (23.92%)
Low 115.00 (Bernstein, 4.78%) Hold
Average 135.43 (23.40%)
Total 5 Buy, 2 Hold
Avg. Price @ Call 110.76
Firm Date Target Price Call Price @ Call
Bernstein 17 Oct 2024 115.00 (4.78%) Hold 109.75
Truist Securities 09 Oct 2024 132.00 (20.27%) Buy 110.27
UBS 09 Oct 2024 136.00 (23.92%) Buy 110.27
31 Jul 2024 142.00 (29.38%) Buy 113.13
Barclays 07 Oct 2024 140.00 (27.56%) Buy 108.59
31 Jul 2024 142.00 (29.38%) Buy 113.13
Cantor Fitzgerald 03 Oct 2024 155.00 (41.23%) Buy 110.18
16 Sep 2024 155.00 (41.23%) Buy 117.96
B of A Securities 31 Jul 2024 145.00 (32.12%) Buy 113.13
Wells Fargo 31 Jul 2024 125.00 (13.90%) Hold 113.13

No data within this time range.

  • 3M
Date Type Details
17 Oct 2024 Announcement Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
17 Oct 2024 CNBC Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
16 Oct 2024 Announcement Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
14 Oct 2024 Announcement Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
09 Oct 2024 Announcement New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
08 Oct 2024 Announcement Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
01 Oct 2024 Announcement Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
01 Oct 2024 Announcement Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
26 Sep 2024 Announcement Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
25 Sep 2024 Announcement Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
25 Sep 2024 Announcement Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
24 Sep 2024 Announcement Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
20 Sep 2024 Announcement Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
18 Sep 2024 Announcement FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
17 Sep 2024 Announcement Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
16 Sep 2024 Announcement PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
15 Sep 2024 Announcement KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
15 Sep 2024 Announcement Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
14 Sep 2024 Announcement KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
14 Sep 2024 Announcement Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
14 Sep 2024 Announcement KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
11 Sep 2024 Announcement Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
11 Sep 2024 Announcement Merck to Participate in the Bank of America 2024 Global Healthcare Conference
07 Sep 2024 Announcement Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
04 Sep 2024 Announcement Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
04 Sep 2024 Announcement Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
03 Sep 2024 Announcement European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
29 Aug 2024 Announcement Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
29 Aug 2024 Announcement Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
27 Aug 2024 Announcement Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
26 Aug 2024 Announcement Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
15 Aug 2024 CNBC What's next for the Biden administration's Medicare drug price negotiations
15 Aug 2024 CNBC Biden administration releases prices of 10 drugs in Medicare negotiations, says U.S. will save $6 billion in first year
09 Aug 2024 Announcement Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
08 Aug 2024 Announcement Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
06 Aug 2024 Announcement Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
01 Aug 2024 Announcement IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
01 Aug 2024 CNBC Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine market
30 Jul 2024 Announcement Merck Announces Second-Quarter 2024 Financial Results
30 Jul 2024 CNBC Merck shares fall 9% despite earnings beat, strong demand for top drugs like Keytruda
26 Jul 2024 Announcement Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
23 Jul 2024 Announcement Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
23 Jul 2024 Announcement Merck Announces Fourth-Quarter 2024 Dividend
Show more
TTM Dividend Yield 2.81%
5Y Average Dividend Yield 2.84%
Payout Ratio 56.30%
Expected Next Dividend Payment Jan 2025
Ex Date Announcement Date Payment Date Details
16 Sep 2024 23 Jul 2024 07 Oct 2024 0.77 Cash
17 Jun 2024 28 May 2024 08 Jul 2024 0.77 Cash
14 Mar 2024 23 Jan 2024 05 Apr 2024 0.77 Cash
14 Dec 2023 28 Nov 2023 08 Jan 2024 0.77 Cash
14 Sep 2023 25 Jul 2023 06 Oct 2023 0.73 Cash
14 Jun 2023 23 May 2023 10 Jul 2023 0.73 Cash
14 Mar 2023 24 Jan 2023 10 Apr 2023 0.73 Cash
14 Dec 2022 29 Nov 2022 09 Jan 2023 0.73 Cash
14 Sep 2022 26 Jul 2022 07 Oct 2022 0.69 Cash
14 Jun 2022 24 May 2022 08 Jul 2022 0.69 Cash
14 Mar 2022 25 Jan 2022 07 Apr 2022 0.69 Cash
14 Dec 2021 30 Nov 2021 07 Jan 2022 0.69 Cash
14 Sep 2021 27 Jul 2021 07 Oct 2021 0.65 Cash
14 Jun 2021 25 May 2021 07 Jul 2021 0.65 Cash
12 Mar 2021 26 Jan 2021 07 Apr 2021 0.65 Cash
14 Dec 2020 17 Nov 2020 08 Jan 2021 0.65 Cash
14 Sep 2020 28 Jul 2020 07 Oct 2020 0.61 Cash
12 Jun 2020 26 May 2020 07 Jul 2020 0.61 Cash
13 Mar 2020 28 Jan 2020 07 Apr 2020 0.61 Cash
13 Dec 2019 20 Nov 2019 08 Jan 2020 0.61 Cash
13 Sep 2019 24 Jul 2019 07 Oct 2019 0.55 Cash
14 Jun 2019 29 May 2019 08 Jul 2019 0.55 Cash
14 Mar 2019 30 Jan 2019 05 Apr 2019 0.55 Cash
14 Dec 2018 26 Oct 2018 08 Jan 2019 0.55 Cash
14 Sep 2018 25 Jul 2018 05 Oct 2018 0.48 Cash
14 Jun 2018 23 May 2018 09 Jul 2018 0.48 Cash
14 Mar 2018 24 Jan 2018 06 Apr 2018 0.48 Cash
14 Dec 2017 29 Nov 2017 08 Jan 2018 0.48 Cash
14 Sep 2017 26 Jul 2017 06 Oct 2017 0.47 Cash
13 Jun 2017 24 May 2017 10 Jul 2017 0.47 Cash
13 Mar 2017 28 Feb 2017 07 Apr 2017 0.47 Cash
13 Dec 2016 22 Nov 2016 09 Jan 2017 0.47 Cash
13 Sep 2016 26 Jul 2016 07 Oct 2016 0.46 Cash
13 Jun 2016 25 May 2016 08 Jul 2016 0.46 Cash
11 Mar 2016 24 Feb 2016 07 Apr 2016 0.46 Cash
11 Dec 2015 24 Nov 2015 08 Jan 2016 0.46 Cash
11 Sep 2015 22 Jul 2015 07 Oct 2015 0.45 Cash
11 Jun 2015 26 May 2015 08 Jul 2015 0.45 Cash
12 Mar 2015 24 Feb 2015 08 Apr 2015 0.45 Cash
11 Dec 2014 25 Nov 2014 08 Jan 2015 0.45 Cash
11 Sep 2014 23 Jul 2014 07 Oct 2014 0.44 Cash
12 Jun 2014 27 May 2014 08 Jul 2014 0.44 Cash
13 Mar 2014 25 Feb 2014 07 Apr 2014 0.44 Cash
12 Dec 2013 26 Nov 2013 08 Jan 2014 0.44 Cash
12 Sep 2013 23 Jul 2013 07 Oct 2013 0.43 Cash
13 Jun 2013 28 May 2013 08 Jul 2013 0.43 Cash
13 Mar 2013 26 Feb 2013 05 Apr 2013 0.43 Cash
13 Dec 2012 27 Nov 2012 08 Jan 2013 0.43 Cash
13 Sep 2012 24 Jul 2012 05 Oct 2012 0.42 Cash
13 Jun 2012 22 May 2012 09 Jul 2012 0.42 Cash
13 Mar 2012 28 Feb 2012 06 Apr 2012 0.42 Cash
13 Dec 2011 10 Nov 2011 09 Jan 2012 0.42 Cash
13 Sep 2011 26 Jul 2011 07 Oct 2011 0.38 Cash
13 Jun 2011 24 May 2011 08 Jul 2011 0.38 Cash
11 Mar 2011 22 Feb 2011 07 Apr 2011 0.38 Cash
13 Dec 2010 23 Nov 2010 07 Jan 2011 0.38 Cash
13 Sep 2010 27 Jul 2010 07 Oct 2010 0.38 Cash
11 Jun 2010 26 May 2010 08 Jul 2010 0.38 Cash
11 Mar 2010 23 Feb 2010 07 Apr 2010 0.38 Cash
11 Dec 2009 24 Nov 2009 08 Jan 2010 0.38 Cash
02 Sep 2009 28 Jul 2009 01 Oct 2009 0.38 Cash
04 Jun 2009 27 May 2009 01 Jul 2009 0.38 Cash
04 Mar 2009 24 Feb 2009 01 Apr 2009 0.38 Cash
03 Dec 2008 25 Nov 2008 02 Jan 2009 0.38 Cash
03 Sep 2008 22 Jul 2008 01 Oct 2008 0.38 Cash
04 Jun 2008 27 May 2008 01 Jul 2008 0.38 Cash
05 Mar 2008 26 Feb 2008 01 Apr 2008 0.38 Cash
05 Dec 2007 27 Nov 2007 02 Jan 2008 0.38 Cash
05 Sep 2007 24 Jul 2007 01 Oct 2007 0.38 Cash
06 Jun 2007 22 May 2007 02 Jul 2007 0.38 Cash
07 Mar 2007 27 Feb 2007 02 Apr 2007 0.38 Cash
06 Dec 2006 28 Nov 2006 02 Jan 2007 0.38 Cash
30 Aug 2006 25 Jul 2006 02 Oct 2006 0.38 Cash
31 May 2006 23 May 2006 03 Jul 2006 0.38 Cash
31 Aug 2005 26 Jul 2005 03 Oct 2005 0.38 Cash
01 Jun 2005 24 May 2005 01 Jul 2005 0.38 Cash
02 Mar 2005 22 Feb 2005 01 Apr 2005 0.38 Cash
01 Dec 2004 23 Nov 2004 03 Jan 2005 0.38 Cash
01 Sep 2004 27 Jul 2004 01 Oct 2004 0.38 Cash
02 Jun 2004 25 May 2004 01 Jul 2004 0.37 Cash
03 Mar 2004 24 Feb 2004 01 Apr 2004 0.37 Cash
03 Dec 2003 25 Nov 2003 02 Jan 2004 0.37 Cash
03 Sep 2003 22 Jul 2003 01 Oct 2003 0.37 Cash
04 Jun 2003 27 May 2003 01 Jul 2003 0.36 Cash
05 Mar 2003 25 Feb 2003 01 Apr 2003 0.36 Cash
04 Dec 2002 26 Nov 2002 02 Jan 2003 0.36 Cash
04 Sep 2002 23 Jul 2002 01 Oct 2002 0.36 Cash
05 Jun 2002 28 May 2002 01 Jul 2002 0.35 Cash
06 Mar 2002 26 Feb 2002 01 Apr 2002 0.35 Cash
05 Dec 2001 27 Nov 2001 02 Jan 2002 0.35 Cash
30 Aug 2001 24 Jul 2001 01 Oct 2001 0.35 Cash
31 May 2001 22 May 2001 02 Jul 2001 0.34 Cash
07 Mar 2001 27 Feb 2001 02 Apr 2001 0.34 Cash
06 Dec 2000 28 Nov 2000 02 Jan 2001 0.34 Cash
30 Aug 2000 25 Jul 2000 02 Oct 2000 0.34 Cash
31 May 2000 22 May 2000 03 Jul 2000 0.29 Cash
01 Mar 2000 22 Feb 2000 03 Apr 2000 0.29 Cash
01 Dec 1999 23 Nov 1999 03 Jan 2000 0.29 Cash
01 Sep 1999 27 Jul 1999 01 Oct 1999 0.29 Cash
02 Jun 1999 25 May 1999 01 Jul 1999 0.27 Cash
03 Mar 1999 23 Feb 1999 01 Apr 1999 0.27 Cash
02 Dec 1998 24 Nov 1998 04 Jan 1999 0.54 Cash
02 Sep 1998 28 Jul 1998 01 Oct 1998 0.54 Cash
03 Jun 1998 26 May 1998 01 Jul 1998 0.45 Cash
04 Mar 1998 24 Feb 1998 01 Apr 1998 0.45 Cash
03 Dec 1997 25 Nov 1997 02 Jan 1998 0.45 Cash
03 Sep 1997 22 Jul 1997 01 Oct 1997 0.45 Cash
05 Jun 1997 28 May 1997 01 Jul 1997 0.42 Cash
05 Mar 1997 25 Feb 1997 01 Apr 1997 0.42 Cash
05 Dec 1996 26 Nov 1996 02 Jan 1997 0.4 Cash
04 Sep 1996 23 Jul 1996 01 Oct 1996 0.4 Cash
06 Jun 1996 29 May 1996 01 Jul 1996 0.34 Cash
06 Mar 1996 27 Feb 1996 01 Apr 1996 0.34 Cash
06 Dec 1995 28 Nov 1995 02 Jan 1996 0.34 Cash
05 Sep 1995 25 Jul 1995 02 Oct 1995 0.34 Cash
02 Jun 1995 23 May 1995 03 Jul 1995 0.3 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 3.08 4 2.81
2023 2.92 4 2.68
2022 2.76 4 2.49
2021 2.60 4 3.39
2020 2.44 4 3.13
2019 2.20 4 2.54
2018 1.92 4 2.63
2017 1.88 4 3.50
2016 1.84 4 3.28
2015 1.80 4 3.57
2014 1.76 4 3.25
2013 1.72 4 3.60
2012 1.68 4 4.30
2011 1.52 4 4.23
2010 1.52 4 4.42
2009 1.52 4 4.36
2008 1.52 4 5.24
2007 1.52 4 2.74
2006 0.760 2 1.83
2005 1.52 4 5.01
2004 1.49 4 4.86
2003 1.45 4 3.29
2002 1.41 4 2.61
2001 1.37 4 2.44
2000 1.21 4 1.35
1999 1.37 4 2.14
1998 1.89 4 2.69
1997 1.69 4 3.34
1996 1.42 4 3.74
1995 0.640 2 2.04
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria